<DOC>
	<DOCNO>NCT00096018</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fludarabine , work different way stop cancer cell divide stop grow die . Biological therapy thalidomide use different way stimulate immune system stop cancer cell grow . Combining fludarabine thalidomide may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose thalidomide give together fludarabine see well work treat patient newly diagnose B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Fludarabine Thalidomide Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety efficacy fludarabine thalidomide patient newly diagnose B-cell chronic lymphocytic leukemia . - Determine overall response rate ( complete partial ) patient treat regimen . - Determine duration response patient treat regimen . OUTLINE : This open-label , phase I , dose-escalation study thalidomide follow phase II study . - Phase I : Beginning day 1 , patient receive oral thalidomide daily 6 month . Beginning day 7 , patient also receive fludarabine IV 30 minute daily 5 day . Treatment fludarabine repeat every 28-35 day 6 course . Treatment continue absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos thalidomide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive fludarabine thalidomide phase I MTD . Patients follow 4 week , every 3 month 2 year , every 4 month 2 year . PROJECTED ACCRUAL : Up 45 patient ( ≥ 9 phase I portion ≤ 36 phase II portion ) accrue study within 8 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis Bcell chronic lymphocytic leukemia ( CLL ) base follow criterion : Peripheral blood lymphocytosis &gt; 5,000/mm^3 Coexpression CD5 , CD19 CD20 , CD23 surface antigens Clonal kappa lambda light chain expression No recurrent refractory CLL No lymphoproliferative disease disease due transformation CLL , prolymphocytic leukemia Richter 's syndrome PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy At least 12 week Hematopoietic See Disease Characteristics Hepatic Bilirubin &lt; 1.5 mg/dL AST &lt; 2.5 time upper limit normal Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No cardiac arrhythmia within past 6 month No myocardial infarction within past 6 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use least 1 highly active 1 additional method contraception 4 week , , least 4 week study treatment Patients must sufficient mental capacity understand study explanation provide informed consent No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No active serious infection uncontrolled antibiotic No medical condition reason would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior therapy CLL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
</DOC>